PDF(Pubmed)
Abstract：
Limited data on the clinical management of drug-drug interactions between triazoles and Cystic Fibrosis transmembrane conductance regulator (CFTR) modulators are available. We retrospectively evaluated azole target attainment and dose adaptations in patients from two Dutch CF centres concomitantly receiving triazoles and CFTR modulators. In total, 21 patients with 59 triazole trough concentrations were evaluated. Subtherapeutic concentrations were frequently observed, especially for itraconazole and voriconazole. Of the investigated antifungal agents, posaconazole appears the most preferable option. Our results emphasize the importance of adequate management of this interaction and underpin the added value of therapeutic drug monitoring of triazoles in this population.
Fungal infections are serious complications in Cystic Fibrosis (CF) patients. We evaluated patients concomitantly receiving triazoles and CF transmembrane conductance regulator modulators: subtherapeutic triazole exposure was frequently observed. Posaconazole appears the preferable antifungal agent.
Fungal infections are serious complications in Cystic Fibrosis (CF) patients. We evaluated patients concomitantly receiving triazoles and CF transmembrane conductance regulator modulators: subtherapeutic triazole exposure was frequently observed. Posaconazole appears the preferable antifungal agent.
摘要：
有关三唑和囊性纤维化跨膜传导调节剂（CFTR）调节剂之间的药物-药物相互作用的临床管理的数据有限。我们回顾性评估了来自两个荷兰CF中心同时接受三唑和CFTR调节剂的患者的唑类药物目标实现和剂量适应。总的来说,评估了21例59个三唑谷浓度的患者。经常观察到亚治疗浓度，尤其是伊曲康唑和伏立康唑。在研究的抗真菌剂中，泊沙康唑似乎是最优选的选择。我们的结果强调了对这种相互作用进行适当管理的重要性，并支持了该人群中三唑类药物治疗药物监测的附加值。
真菌感染是囊性纤维化（CF）患者的严重并发症。我们评估了同时接受三唑和CF跨膜传导调节剂的患者：经常观察到亚治疗性三唑暴露。泊沙康唑似乎是优选的抗真菌剂。
真菌感染是囊性纤维化（CF）患者的严重并发症。我们评估了同时接受三唑和CF跨膜传导调节剂的患者：经常观察到亚治疗性三唑暴露。泊沙康唑似乎是优选的抗真菌剂。
